Overview

6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients

Status:
Unknown status

Trial end date:
2019-02-01

Target enrollment:

Participant gender:

Summary

In low-risk node-negative breast cancer patients adjuvant chemotherapy should be spared. The identification of this subgroup can be based either on clinical and pathological or on tumour-biological criteria. Due to their high prognostic impact, the tumour-biological invasion markers uPA/PAI-1 (urokinase-type plasminogen activator and its inhibitor PAI-1) are potential candidates to effectively assess the risk of relapse in node-negative breast cancer. This study is aimed to compare the risk assessment by the traditional clinico-pathological factors and by tumour-biological factors. The second study question refers to the comparison between an adjuvant combination treatment with FE100C*6 and a sequential treatment with FE100C*3 and Docetaxel*3.

Phase:

Phase 3

Details

Lead Sponsor:

Martin-Luther-Universität Halle-Wittenberg

Collaborator:

German Breast Group

Treatments:

Cyclophosphamide
Docetaxel
Epirubicin
Fluorouracil
Plasminogen